A probable mechanism for hyperpigmentation by fotemustine.
Schallreuter
K U
KU
Ring
J
J
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D009607:Nitrosourea Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D009943:Organophosphorus Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D010859:Pigmentation Disorders / Q000139:chemically induced*; D013880:Thioredoxin-Disulfide Reductase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D013880:Thioredoxin-Disulfide Reductase; C054368:fotemustine